TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04176250
Drug: TBA-7371
Normalized name: TBA-7371
DrugBank: TBA-7371 (DB16243)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive TBA-7371 oral suspension 100 milligram (mg) once daily (QD) for 14 days.
Study: NCT04176250
Drug: TBA-7371
Normalized name: TBA-7371
DrugBank: TBA-7371 (DB16243)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive TBA-7371 oral suspension 100 mg twice daily (BID) for 14 days.
Study: NCT04176250
Drug: TBA-7371
Normalized name: TBA-7371
DrugBank: TBA-7371 (DB16243)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive TBA-7371 oral suspension 200 mg QD for 14 days.
Study: NCT04176250
Drug: TBA-7371
Normalized name: TBA-7371
DrugBank: TBA-7371 (DB16243)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive TBA-7371 oral suspension 100 mg three times daily (TID) for 14 days.
Study: NCT04176250
Drug: TBA-7371
Normalized name: TBA-7371
DrugBank: TBA-7371 (DB16243)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive TBA-7371 oral suspension 400 mg QD for 14 days.
Study: NCT04176250
Drug: HRZE
Normalized name: Isoniazid, Rifampicin, Pyrazinamide, Ethambutol
DrugBank: Ethambutol (DB00330)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive Isoniazid \[H\] / rifampicin \[R\] / pyrazinamide \[Z\] / ethambutol \[E\] (HRZE), a fixed dose combination tablet QD for 14 days, based on weight as 40-54 kilograms (kg): 3 tablets; 55-70 kg: 4 tablets and 71 kg and over: 5 tablets.
Study: NCT00633997
Drug: Vildagliptin
Normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: 50 mg orally twice daily for 10 days (last dose morning of day 10)
Study: NCT00633997
Drug: Vildagliptin
Normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT01623908
Drug: Zoledronate
Normalized name: Zoledronate
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4mg, IV (in the vein) every 6 months. Number of Cycles: up to the researcher or until unacceptable toxicity develops.
Study: NCT00095446
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00264901
Drug: insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01639157
Drug: Buspirone
Normalized name: Buspirone
DrugBank: Buspirone (DB00490)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be maintained on oral buspirone (10 mg administered 3 times daily) for 6 days each during the study in random order.
Study: NCT04347733
Drug: Triamcinolone Acetonide 40mg/mL
Normalized name: TRIAMCINOLONE ACETONIDE 40MG/ML INJ,SUSP
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: We aimed to examine the therapeutic efficacy of the combination of hyaluronidase and steroid injection for adhesive capsulitis and to determine whether such a combination therapy might enable the total amount of steroids to be reduced.
Study: NCT04347733
Drug: Hyaluronidase Injection
Normalized name: hyaluronidase Injection
DrugBank: Hyaluronidase (ovine) (DB00070)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: We aimed to examine the therapeutic efficacy of the combination of hyaluronidase and steroid injection for adhesive capsulitis and to determine whether such a combination therapy might enable the total amount of steroids to be reduced.
Study: NCT03172871
Drug: Aripiprazole IM Depot
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole IM depot 400 mg/300 mg (when not tolerated)
Study: NCT03172871
Drug: Aripiprazole tablet
Normalized name: Aripiprazole Tablets
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral aripiprazole tablets 10 to 20 mg daily
Study: NCT00564421
Drug: epinastine nasal spray, low concentration, low dose volume
DrugBank: Epinastine (DB00751)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 sprays in each nostril, dosed twice a day
Study: NCT00564421
Drug: epinastine nasal spray, low concentration, high dose volume
DrugBank: Epinastine (DB00751)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 sprays in each nostril, dosed twice a day
Study: NCT00564421
Drug: epinastine nasal spray, high concentration, low dose volume
DrugBank: Epinastine (DB00751)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 sprays in each nostril, dosed twice a day
Study: NCT00564421
Drug: epinastine nasal spray, high concentration, high dose volume
DrugBank: Epinastine (DB00751)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 sprays in each nostril, dosed twice a day
Study: NCT02852252
Drug: ICG
Normalized name: ICG136
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be given imaging agent 24 hours before surgery to assist in imaging.
Study: NCT00355888
Drug: MBP-426
Normalized name: MBP
DrugBank: Myelin basic protein (DB16952)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation starting at 6 mg/m2, IV (in the vein) on Day 1 of each 21-day cycle. Number of Cycles: Up to 6 cycles, until unacceptable toxicity, disease progression, or intercurrent illness requires treatment discontinuation. Patients may continue treatment beyond 6 cycles if the Investigator determines that additional treatment would provide further benefit for the patient as long as toxicity remains acceptable.
Study: NCT00367653
Drug: Mefloquine
Normalized name: Mefloquine
DrugBank: Mefloquine (DB00358)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mefloquine 1250 mg PO given as a split dose (750 mg \[three 250 mg capsules\]) initial dose followed by 500 mg PO (two 250 mg capsules) given 6 to 10 hours later on Day 0
Study: NCT00978016
Drug: arbaclofen placarbil-Cohort 1
Normalized name: baclofen 1 MG/ML
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 20 mg QD) for 7 weeks including titration and taper periods
Study: NCT00978016
Drug: arbaclofen placarbil-Cohort 2
Normalized name: baclofen 2 MG/ML
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 40 mg QD) with for 7 weeks including titration and taper periods
Study: NCT00978016
Drug: arbaclofen placarbil-Cohort 3
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 20 mg BID) for 7 weeks including titration and taper periods
Study: NCT00978016
Drug: arbaclofen placarbil-Cohort 4
Normalized name: baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 30 mg BID) for 7 weeks including titration and taper periods
Study: NCT02111096
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered orally
Study: NCT02111096
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered orally
Study: NCT05024825
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in the gabapentin arm may at any point call the Pediatric ENT clinic if pain is not adequately controlled. Patients will be prescribed hydrocodone acetaminophen solution 7.5mg-325mg/15mL 5mL for ages 12-14 yrs and 10 mL for ages 15-18yrs, q 4-6 hours as needed for pain. Patients will be informed to stop taking gabapentin.
Study: NCT04659369
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: for injection only
Study: NCT02766335
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02271295
Drug: Enoxaparine
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparine 4000UI/day during 24 months
Study: NCT04578535
Drug: HYQVIA
Normalized name: Hyqvia
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received a SC infusion of HYQVIA 0.1 g/kg (1/4 of TDL) on Day 1 and 8, 0.2 g/kg (1/2 of TDL) on Day 15, 0.3 g/kg (3/4 of TDL) on Day 29 followed by 0.4 g/kg (full TDL) on Day 50 in Ramp-Up dosing manner.
Study: NCT04578535
Drug: HYQVIA
Normalized name: Hyqvia
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received a SC infusion of HYQVIA 0.25 g/kg (1/4 of TDL) on Day 1 and 8, 0.5 g/kg (1/2 of TDL) on Day 15, 0.75 g/kg (3/4 of TDL) on Day 29 followed by 1.0 g/kg (full TDL) on Day 50 in Ramp-Up dosing manner.
Study: NCT04578535
Drug: HYQVIA
Normalized name: Hyqvia
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received a SC infusion of HYQVIA 0.2 g/kg (1/2 of TDL) on Day 1 and 15, followed by 0.4 g/kg (full TDL) on Day 29 and 57 in Ramp-Up dosing manner.
Study: NCT04578535
Drug: HYQVIA
Normalized name: Hyqvia
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received a SC infusion of HYQVIA 0.5 g/kg (1/2 of TDL) on Day 1 and 15, followed by 1.0 g/kg (full TDL) on Day 29 and 57 in Ramp-Up dosing manner.
Study: NCT04578535
Drug: HYQVIA
Normalized name: Hyqvia
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received a SC infusion of HYQVIA 0.4 g/kg (full TDL) SC infusion on Day 1, 29 and 57 without Ramp-Up dosing manner.
Study: NCT04578535
Drug: HYQVIA
Normalized name: Hyqvia
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received a SC infusion of HYQVIA 1.0 g/kg (full TDL) SC infusion on Day 1, 29 and 57 without Ramp-Up dosing manner.
Study: NCT00825786
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ropivacaine (15 ml).
Study: NCT00825786
Drug: Mepivacaine
Normalized name: Mepivacaine
DrugBank: Mepivacaine (DB00961)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One syringe will contain mepivacaine (15 ml)
Study: NCT03557112
Drug: Nimotuzumab
Normalized name: nimotuzumab
DrugBank: Nimotuzumab (DB06192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPF Regimen Induction Chemotherapy combined with nimotuzumab concurrent radiotherapy concurrent chemoradiotherapy
Study: NCT03557112
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TPF Regimen Induction Chemotherapy combined with cisplatin concurrent radiotherapy concurrent chemoradiotherapy
Study: NCT02756611
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets for oral administration
Study: NCT01470092
Drug: Tibolone
Normalized name: TIBOLONE
DrugBank: Tibolone (DB09070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take 2.5mg of oral Tibolone daily for the duration of the 12 week trial either alone or in adjunct to currently prescribed antidepressant medication.
Study: NCT02023931
Drug: Broccoli Sprout Extract (BSE)
Normalized name: broccoli sprout extract
DrugBank: Broccoli (DB10511)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. The first regimen will involve oral delivery and ingestion of 600 μmole doses of glucoraphanin-rich BSE (GRR-BSE), and will represent systemic delivery of sulforaphane to oral mucosa, due to the necessity to metabolize GRR-BSE in the gut.~2. The second regimen will involve oral delivery and ingestion of 100 μmole doses of sulforaphane-rich BSE (SFR-BSE), which will represent a combination of systemic and topical delivery to the oral mucosa.~3. The third regimen will isolate topical exposure of the oral mucosa to sulforaphane. Participants will swish, hold, then spit 100 μmole doses of SFR-BSE. This regimen (SFR-BSE(T)) will theoretically isolate the pharmacodynamic impact of topical exposure of the oral mucosa to sulforaphane.
Study: NCT02127749
Drug: Vancomycin, Metronidazole, Ciprofloxacin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ciprofloxacin 500mg 2 times per day, vancomycin 500mg 3 times per day metronidazole 500mg 3 times per day All together during 7 days
Study: NCT00926354
Drug: AS101
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous infusions of 3mg/m2 AS101 twice a week in addition to the standard chemotherapy regimen during the following 4 chemotherapy courses.
Study: NCT02187536
Drug: Telmisartan
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02187536
Drug: Telmisartan placebo
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03869944
Drug: Lamivudine Oral Solution
Normalized name: Lamivudine Oral Solution
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: During the EPI-2 visit, HIV-1 negative children of mothers with a unsuppressed plasma HIV-1 VL (≥ 1000 copies/mL) will be initiated on PrEP, lamivudine syrup (7.5 mg twice daily if 2 to 4 kg; 25 mg twice a day if weight \<8 kg; and 50 mg twice a day if weight \>8 kg) for 10 months, until the child is 12 months old. A monitoring on the mother's VL and child's diagnosis will take place at 6 and 12 months.~Mothers with unsuppressed plasma HIV-1 VL (\< 1000 copies/mL) and HIV-1 negative children will not be offered PrEP but the mother's VL and child diagnosis will be monitored at 6 and 12 months: If the VL is ≥ 1000 copies/mL, the child will be initiated on PrEP until the child is 12 months old.~Children infected with HIV-1 will be referred to the National Program for immediate ART.
Study: NCT02920801
Drug: saxagliptin
Normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5mg per day for 12 weeks
Study: NCT02920801
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1500mg per day for 12 weeks
Study: NCT00307086
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: the maximum tolerated dose (MTD) of bortezomib in combination with high-dose melphalan as a conditioning regimen for autologous stem cell transplant
Study: NCT00307086
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Day -4 melphalan 100 mg/m2 intravenously over 30 minutes, Day -3 melphalan 100 mg/m2 intravenously over 30 minutes
Study: NCT01354444
Drug: Carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: target dose of 25 mg daily which is half the maximum dose used in clinical practice
Study: NCT04334317
Drug: TAK-071
Normalized name: TAK-071
DrugBank: TAK-071 (DB18954)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-071 tablet.
Study: NCT00147719
Drug: Colesevelam hydrochloride
Normalized name: Colesevelam Hydrochloride
DrugBank: Colesevelam (DB00930)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05485818
Drug: Middle Dose
Normalized name: wheat middlings extract
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12±4 hours after PCI: 0.5 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：0.5 ug/kg Recombinant Human Thymosin β4 （intravenous injection）
Study: NCT02263963
Drug: Exparel
Normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In this arm as described above the intervention will be TAP block injection under ultrasound guidance using Exparel.
Study: NCT00879086
Drug: Eribulin Mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: E7389 (eribulin mesylate) given at a dose of 1.4 mg/m\^2 as a 2 to 5 minute intravenous (IV) bolus on Days 1 and 8 of a 21-day cycle.~The Treatment Phase will include six cycles. Patients may enter the Extension Phase for additional cycles following the sixth cycle of treatment.
Study: NCT00879086
Drug: Ixabepilone
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ixabepilone given at a starting dose of 32 or 40 mg/m\^2 (as per approved labeling) as a 3-hour IV infusion on Day 1 of a 21-day cycle.~The Treatment Phase will include six cycles. Patients may enter the Extension Phase for additional cycles following the sixth cycle of treatment.
Study: NCT02969044
Drug: PF-06651600
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg pill every day (QD) for 8 weeks
Study: NCT03153358
Drug: Icotinib
Normalized name: icotinib
DrugBank: Icotinib (DB11737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: icotinib 125 milligram three times a day
Study: NCT00327418
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00890617
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone taken:~20mg BID on the day of the cryotherapy procedure 20mg BID on the day after the procedure 20mg BID two days after the procedure 20mg AM and 10mg PM three days after the procedure 10mg AM and 10mg PM four days after the procedure 10mg five days after the procedure 5mg six days after the procedure
Study: NCT06030375
Drug: KAND567
Normalized name: KAND567
DrugBank: KAND567 (DB16511)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion for 6 hours
Study: NCT04650204
Drug: Perampanel
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT01683396
Drug: gevokizumab
Normalized name: Gevokizumab
DrugBank: Gevokizumab (DB12119)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for subcutaneous injection
Study: NCT00681343
Drug: Thymoglobulin
Normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction
Study: NCT00681343
Drug: Daclizumab
Normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Induction
Study: NCT03903302
Drug: CS1-Sodium Valproate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single and multiple dose evaluation of CS1
Study: NCT04356989
Drug: Rivaroxaban (Xarelto, BAY59-7939)
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The adminstration dose is decided by the attending physician in advance based on the patients' CrCl and in compliance with local market authorization of rivaroxaban.
Study: NCT03308214
Drug: Imipenem
Normalized name: Imipenem
DrugBank: Imipenem (DB01598)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Imipenem 1.0 q 8h
Study: NCT00312338
Drug: VIGAMOX
Normalized name: Vigamox
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 drop of VIGAMOX® ophthalmic solution 0.5% in both eyes TID for 7 days
Study: NCT04968613
Drug: Madopar monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In addition to basic treatment, the patient also received Madopar treatment
Study: NCT04968613
Drug: senfrol monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In addition to the basic treatment, the patient also received the rofosson treatment
Study: NCT02501928
Drug: Fesoterodine PR 4 mg
Normalized name: fesoterodine fumarate 4 MG
DrugBank: Fesoterodine (DB06702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fesoterodine 4 mg tablet once daily for 28 or 40 weeks
Study: NCT02501928
Drug: Fesoterodine PR 8 mg
Normalized name: fesoterodine fumarate 8 MG
DrugBank: Fesoterodine (DB06702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fesoterodine PR 8 mg tablet once daily for 28 or 40 weeks
Study: NCT02501928
Drug: Fesoterodine BIC 4 mg
Normalized name: fesoterodine fumarate 4 MG
DrugBank: Fesoterodine (DB06702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fesoterodine BIC 4 mg tablet once daily for 28 weeks
Study: NCT00929851
Drug: Formoterol fumarate
Normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formoterol fumarate 12 µg per metered dose
Study: NCT00036153
Drug: Tacrolimus (Prograf®)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00428272
Drug: Lexatumumab alone
Normalized name: Lexatumumab
DrugBank: Lexatumumab (DB06599)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation : 3mg/kg, 5mg/kg, 8mg/kg, 10mg/kg
Study: NCT00428272
Drug: Lexatumumab in combination
Normalized name: Lexatumumab
DrugBank: Lexatumumab (DB06599)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation : 1mg/kg, 3mg/kg, 5mg/kg, 8mg/kg, 10mg/kg
Study: NCT00428272
Drug: Interferon gamma 1b in combination
Normalized name: Interferon Gamma-1B
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing at the following for each lexatumumab dose level: .75mcg/m2/dose and 25mcg/m2/dose
Study: NCT00428272
Drug: Gamma 1b potential expansion
Normalized name: Interferon Gamma-1B
DrugBank: Interferon gamma-1b (DB00033)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potential expansion (at 10mg/kg lexatumumab): 1.5mcg/m2/dose and 50mcg/m2/dose
Study: NCT01197911
Drug: aleglitazar
Normalized name: Aleglitazar
DrugBank: Aleglitazar (DB08915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose
Study: NCT03106324
Drug: Revlimid (lenalidomide)
Normalized name: lenalidomide Oral Capsule [Revlimid]
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment with first line Revlimid containing regimen as prescribed in routine clinical practice
Study: NCT06568224
Drug: Mesalazine
Normalized name: mesalazine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral mesalazine 1g qid
Study: NCT02020278
Drug: Tolvaptan
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tolvaptan 3.75-, 7.5-, 15-, and 30-mg spray-dried tablets. Dosage: Depending on age and weight, Tablet (3.75 mg - 60 mg daily). Frequency: Once daily.~Duration: Participants may be eligible to receive short-term or long-term optional tolvaptan treatment at any time during their participation in the trial, with one or more treatment cycles over a 6-month period.
Study: NCT01047254
Drug: Elontril
Normalized name: phendimetrazine tartrate Oral Tablet [Bontril]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: flexible dose of Bupropion 150-300 mg